Even at lower doses, GLP-1 receptor activation can reduce appetite, improve insulin sensitivity, and support metabolic function
The product has generated serious buzz in the gut health and peptide and GLP-1 research community
114117 Patients with T2DM are at risk for diabetic kidney disease, especially when hyperglycemia, hypertension, or both conditions are poorly controlled
If you are just beginning your GLP-1 journey and feel overwhelmed by the prospect of researching and purchasing multiple individual supplements, Replenza removes that friction
Other therapeutic areas that are being heavily studied include kidney disease and cardiovascular disease, which are often comorbid with obesity and/or type 2 diabetes
GLP-1 therapies are showing up in ophthalmic practice whether clinicians are ready for them or not, and the evidence on their ocular effects is as mixed as the patients taking them